VENTANA anti-MSH6 (SP93) Antibody
Ventana Medical Systems, Inc. (Roche Tissue Diagnostics) · Decision date Jan 6, 2026
What did the FDA decide?
FDA records P210001/S015 as a supplement to PMA P210001, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jan 6, 2026.
FDA approval order statement
approval of manufacturing process changes
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Pathology
- Decision date
- Jan 6, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P210001/S015
- Regulatory pathway
- PMA supplement
- Product code
- QNH
- Decision code
- OK30
- Decision date
- Jan 6, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Immunohistochemistry test, DNA mismatch repair (MMR) Protein assay.
- Product code
- QNH
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P210001. Subsequent supplements may change the device or its indications.
FDA decision timeline
P210001 · Original PMA
VENTANA MMR RxDx Panel
P210001/S015 received
Application receipt date recorded by FDA.
P210001/S015 · FDA decision
30-Day Notice
P210001/S016 · Related supplement
VENTANA MMR RxDx Panel
Timeline entries are records held by MedtechLedger for P210001. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P210001
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
VENTANA MMR RxDx PanelP210001 | Ventana Medical Systems, Inc. (Roche Tissue Diagnostics) | PMA approval | Aug 17, 2021 | FDA |
VENTANA MMR RxDx PanelP210001/S016 | Ventana Medical Systems, Inc. (Roche Tissue Diagnostics) | PMA supplement | Oct 8, 2026 | FDA |
Explore the linked device profile
Other records with product code QNH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
VENTANA MMR RxDx PanelP200019/S014 | Ventana Medical Systems | PMA supplement | Oct 8, 2026 | FDA |
MMR IHC Panel pharmDx (Dako Omnis)P250004/S001 | Agilent Technologies, Inc. | PMA supplement | Sep 11, 2026 | FDA |
VENTANA anti-MSH6 (SP93) AntibodyP200019/S013 | Ventana Medical Systems | PMA supplement | Jan 6, 2026 | FDA |
| Agilent Technologies, Inc. | PMA approval | Aug 15, 2025 | FDA | |
VENTANA MMR RxDx PanelP200019 | Ventana Medical Systems | PMA approval | Apr 22, 2021 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Ventana Medical Systems, Inc. (Roche Tissue Diagnostics)
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1910 E. Innovation Park Dr., Tucson, AZ, 85755
Sources and methodology
- Original FDA record: P210001/S015
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


